

December 2, 2013



Prague-based Unimedis Acquired by ResMed

Deal will Increase Accessibility of Leading Sleep and Respiratory Therapies in Czech Republic

SAN DIEGO and PRAGUE, Dec. 2, 2013 /PRNewswire/ -- Prague-based Unimedis, a distributor of equipment for the treatment of sleep disordered-breathing in the Czech Republic and Slovakia, has been acquired by ResMed (NYSE: RMD), a pioneer and global leader in sleep and respiratory medicine.

(Logo: <https://photos.prnewswire.com/prnh/20100203/RESMEDLOGO>)

"The Czech and Slovak markets have tremendous growth opportunity for our core business in treating sleep-disordered breathing and for our growing portfolio of respiratory care and cardiology solutions," said ResMed-Europe President Anne Reiser. "This acquisition continues ResMed's emerging market strategy of growing our distribution to bring market-leading sleep-disordered breathing and respiratory care solutions to places where they're needed most." In an earlier example of that strategy, in October ResMed acquired Warsaw-based Mediserv, now known as ResMed-Poland.

"Health care policy in the Czech Republic is shifting to place more value on compliance and outcomes of reimbursed therapies," said Tomasz Zarzycki, commercial director for Emerging Markets in ResMed-Europe. "This policy aligns well with ResMed's solutions, which enhance compliance and facilitate remote compliance management, improving the quality and efficiency of patient care."

Unimedis will continue to serve the entire Czech Republic and Slovakia under the leadership of Ondrej Kalas, who will remain with ResMed as country manager for the Czech Republic and Slovakia.

"Unimedis has always provided excellent service and quality products to our customers and under ResMed's banner, we will continue that record," said Kalas.

The acquisition was completed today. Terms of the deal were not disclosed.

About ResMed:

ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products

to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contacts:

For News Media

Gretchen Griswold

Director, Global Corporate Communications

O: 858-836-6789

news@resmed.com

For Investors

Constance Bienfait

Director, Investor Relations

O: 858-836-5971

constance.bienfait@resmed.com

SOURCE ResMed Inc.